Monitoring blood glucose in pregnant women receiving betamethasone for fetal lung development
Blood Glucose Levels in Pregnant Non-diabetic Women During Treatment With Betamethasone for Fetal Lung Maturation
This study looks at how the medication betamethasone affects blood sugar levels in pregnant women who don't have diabetes but are at risk of preterm birth.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | University of Aarhus Academic / other |
| Locations | 1 site (Aarhus, Central Region Denmark) |
| Trial ID | NCT06794307 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the changes in maternal blood glucose levels in non-diabetic pregnant women receiving betamethasone for fetal lung maturation during threatened preterm birth. Participants will be monitored using continuous glucose monitoring (CGM) to assess glycemic responses over a period of six days. Blood samples will also be collected to measure various metabolic markers, providing a comprehensive understanding of how betamethasone affects glucose homeostasis in this population. The study seeks to fill the knowledge gap regarding the effects of corticosteroids on non-diabetic pregnant women, which has been less explored compared to diabetic counterparts.
Who should consider this trial
Good fit: Ideal candidates for this study are pregnant women between 24 and 34 weeks of gestation who are experiencing symptoms of threatened preterm birth and are planned to receive betamethasone.
Not a fit: Patients with diabetes or those on medications affecting glucose metabolism will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of blood glucose levels in pregnant women receiving betamethasone, potentially enhancing neonatal outcomes.
How similar studies have performed: While studies have shown the effects of betamethasone in diabetic pregnant women, this specific investigation in non-diabetic women is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pregnant in gestational week 24+0 - 34+0 admitted with symptoms of threatened preterm birth: * Premature contractions and shortening of the cervix, or * Preterm premature rupture of membranes. * Treatment with betamethasone for fetal lung maturation is planned, or started (maximum 4 hours before inclusion) * Age over 18 years * Read and understand Danish Exclusion Criteria: * Multiple pregnancy * Diabetes * Pre-existing maternal use of medications that affect glucose metabolism
Where this trial is running
Aarhus, Central Region Denmark
- Aarhus University Hospital — Aarhus, Central Region Denmark, Denmark (Recruiting)
Study contacts
- Study coordinator: Victoria Bøttker
- Email: victoria.boettker@gmail.com
- Phone: +45 21253835
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.